RadNet, Inc. (NASDAQ:RDNT) EVP Sells $1,004,295.00 in Stock

RadNet, Inc. (NASDAQ:RDNT) EVP David Jeffrey Katz sold 12,300 shares of the firm’s stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $81.65, for a total value of $1,004,295.00. Following the completion of the transaction, the executive vice president now owns 62,909 shares of the company’s stock, valued at $5,136,519.85. The trade was a 16.35 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

RadNet Price Performance

Shares of NASDAQ RDNT opened at $81.76 on Friday. The firm has a market cap of $6.05 billion, a P/E ratio of -1,168.00 and a beta of 1.75. The business’s 50 day moving average is $72.43 and its 200-day moving average is $65.02. The company has a current ratio of 2.16, a quick ratio of 2.16 and a debt-to-equity ratio of 0.89. RadNet, Inc. has a 1-year low of $32.37 and a 1-year high of $93.65.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Janus Henderson Group PLC grew its stake in shares of RadNet by 108.6% in the first quarter. Janus Henderson Group PLC now owns 64,029 shares of the medical research company’s stock valued at $3,112,000 after acquiring an additional 33,335 shares in the last quarter. Lisanti Capital Growth LLC acquired a new stake in RadNet in the 3rd quarter worth about $2,922,000. Intech Investment Management LLC bought a new stake in RadNet in the 2nd quarter valued at about $446,000. Steigerwald Gordon & Koch Inc. grew its position in shares of RadNet by 153.9% during the 2nd quarter. Steigerwald Gordon & Koch Inc. now owns 15,470 shares of the medical research company’s stock worth $911,000 after purchasing an additional 9,376 shares in the last quarter. Finally, Pathstone Holdings LLC increased its holdings in shares of RadNet by 58.5% during the third quarter. Pathstone Holdings LLC now owns 27,503 shares of the medical research company’s stock worth $1,908,000 after purchasing an additional 10,151 shares during the period. Institutional investors own 77.90% of the company’s stock.

Analyst Ratings Changes

RDNT has been the topic of a number of analyst reports. Truist Financial upped their price objective on RadNet from $80.00 to $94.00 and gave the stock a “buy” rating in a research note on Friday. Jefferies Financial Group lifted their target price on RadNet from $75.00 to $80.00 and gave the stock a “buy” rating in a research note on Thursday, September 19th. Sidoti raised RadNet to a “strong-buy” rating in a report on Friday, October 4th. Finally, Barclays upgraded shares of RadNet from an “equal weight” rating to an “overweight” rating and upped their price objective for the company from $57.00 to $79.00 in a report on Friday, September 6th. One analyst has rated the stock with a sell rating, four have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, RadNet has a consensus rating of “Moderate Buy” and a consensus target price of $78.25.

About RadNet

RadNet, Inc, together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. The company operates in two segments: Imaging Centers and Artificial Intelligence. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services.